EFM
EPZM

E Fund Management’s Epizyme, Inc EPZM Stock Holding History

E Fund Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,338
Closed -$68K – 319
2021
Q3 		$68K Buy
+13,338
New +$81K ﹤0.01% 265
2021
Q1 		$99K Buy
+11,351
New +$117K 0.01% 242

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

E Fund Management's EPZM Position: Q4 2021 in Review

E Fund Management sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 13,338 shares — an estimated $68K sold.

E Fund Management first reported a position in EPZM in Q1 2021 and held it in 2 quarters. The position peaked at $99K in Q1 2021. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • E Fund Management reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • E Fund Management sold 13,338 Epizyme, Inc shares in Q4 2021, an estimated $68K.
  • E Fund Management first reported a position in Epizyme, Inc in Q1 2021 and held it in 2 quarters.
  • E Fund Management's Epizyme, Inc position peaked at $99K in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on E Fund Management's 13F filing for Q4 2021, filed 11 Feb 2022.